Investors around the world are seeing a ray of hope as the fourth-quarter earnings season kicked off on an encouraging note. Both earnings and sales growth in Q4 are tracking above other recent periods and on track to reach the highest …
Shares of Biogen Inc closed the previous trading session at 271.34 up +0.31 0.11% with 1,376,563 shares trading hands. The post Insider Trading Activity Biogen Inc (NASDAQ:BIIB) – CEO Bought 1,402 shares of Stock appeared first on …
Mr. Jeffrey D. Capello is Chief Financial Officer, Executive Vice President of the Company. Prior to that, Mr. Capello served as the Chief Financial Officer of Beacon Health Options, Inc., a behavioral health company, with responsibility for …
Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in …
Whether it’s a bottom or the bottom isn’t certain. But if you want guarantees in this market, about the best you’re going to find is in Biogen Idec (BIIB). We’ve got an iron-clad trade for BIIB stock with risk that’s 100% contained. I’ll go ...
The Biogen Inc. (Nasdaq: BIIB) stock price was down about 6% this morning (Friday) after the company missed on Q1 earnings – but this slip won't last… Biogen reported earnings per share (EPS) of $3.82 compared to estimates of $3.91. …
The share price of Biogen Inc. (NASDAQ:BIIB) tumbled as much as 8 percent, to $395, Friday after sales of the …
The European Commission (EC) has granted a marketing authorization for SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA), Biogen (NASDAQ: BIIB) announced today.1 5q SMA is the most common form of the …
The Thomson/First Call consensus price target is $176.32. The stock closed Tuesday at $154.24. Biogen Idec Inc. (NASDAQ: BIIB) is another top stock to buy on Wall Street, and many predict that its Tysabri earnings will have a …
Biogen Idec Inc. (NASDAQ: BIIB) is the in-class leader in the sector and a top ... With an incredible pipeline to treat a variety of additional conditions, the stock is well liked across Wall Street, with 16 other firms having rated the stock a Buy.